Analysts noted that Eli Lilly and Company's revenue reached $22.974 billion in Q2 2026, a 47.67% year-over-year increase, with earnings per share (EPS) of $8.38, exceeding market expectations by 27.27%. Company management has raised its full-year revenue guidance to between $85 billion and $87 billion. Additionally, Eli Lilly plans to submit a Biologics License Application (BLA) for its triple-agonist Retatrutide in Q1 2027, which is seen as a key catalyst for the stock price to rise to $1,381.62. Although Eli Lilly's stock price has fallen by 8.61% over the past month, it has still gained 50.72% over the past year.